Utility of Preoperative Staging for Clinically Localized Merkel Cell Carcinoma Preoperative Staging for Localized MCC
Main Article Content
Keywords
Merkel Cell Carcinoma, Skin Cancer, Staging, Imaging, Neuroendocrine Cancer
Abstract
Introduction: For Merkel Cell Carcinoma (MCC), a rare cutaneous neuroendocrine cancer, treatment varies based on disease stage at presentation. For patients with localized disease, primary treatment is surgical resection. There is wide practice variation in the performance of preoperative imaging studies, which may upstage patients and/or change plans for surgical resection. The purpose of this study was to evaluate how preoperative staging with cross-sectional imaging influenced management of patients with clinically localized Merkel Cell Carcinoma.
Methods: We identified patients who were evaluated at our facility between January 1, 2012 and December 31, 2020 for clinically localized MCC (confined to the skin, without evidence of nodal spread or signs/symptoms of distant disease) prior to surgical resection. The primary outcome was the proportion of patients whose management changed based on preoperative imaging.
Results: There were 97 patients, of whom 84 (87%) had preoperative staging studies. Patients had a median age of 75 years, 13% were immunosuppressed, and 81% had tumors <2cm. There were no differences in the clinical characteristics of patient based on whether staging was performed. PET/CT was performed in 52(67%) patients, 51(62%) CT, 31(41%) brain MRI. There were 5 patients with indeterminate findings (all on PET/CT), but there were no patients for whom preoperative staging changed the plan for surgical resection.
Conclusion: There were no changes in surgical management based on results of preoperative imaging. More selective use of preoperative imaging staging may be warranted, potentially considering risk factors for clinically occult micro-metastatic disease.
References
2. Hodgson NC. Merkel cell carcinoma: changing incidence trends. J Surg Oncol 2005;89:1-4. Available at: https://www.ncbi.nlm.nih.gov/pubmed/15611998.
3. Agelli M, Clegg LX. Epidemiology of primary Merkel cell carcinoma in the United States. J Am Acad Dermatol 2003;49:832-841. Available at: http://www.ncbi.nlm.nih.gov/pubmed/14576661.
4. Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 2016;17:1374-1385. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27592805.
5. Colgan MB, Tarantola TI, Weaver AL, et al. The predictive value of imaging studies in evaluating regional lymph node involvement in Merkel cell carcinoma. J Am Acad Dermatol 2012;67:1250-1256. Available at: https://www.ncbi.nlm.nih.gov/pubmed/22552001.
6. Gupta SG, Wang LC, Penas PF, et al. Sentinel lymph node biopsy for evaluation and treatment of patients with Merkel cell carcinoma: The Dana-Farber experience and meta-analysis of the literature. Arch Dermatol 2006;142:685-690. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16785370.
7. Hawryluk EB, O'Regan KN, Sheehy N, et al. Positron emission tomography/computed tomography imaging in Merkel cell carcinoma: a study of 270 scans in 97 patients at the Dana-Farber/Brigham and Women's Cancer Center. J Am Acad Dermatol 2013;68:592-599. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23127473.
8. Liu J, Larcos G, Howle J, Veness M. Lack of clinical impact of (18) F- fluorodeoxyglucose positron emission tomography with simultaneous computed tomography for stage I and II Merkel cell carcinoma with concurrent sentinel lymph node biopsy staging: A single institutional experience from Westmead Hospital, Sydney. Australas J Dermatol 2017;58:99-105. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26459330.
9. Kouzmina M, Koljonen V, Leikola J, et al. Frequency and locations of systemic metastases in Merkel cell carcinoma by imaging. Acta Radiol Open 2017;6:2058460117700449. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28540062.
10. Trends in Use of Medical Imaging in US Health Care Systems and in Ontario, Canada, 2000-2016”: https://jamanetwork.com/journals/jama/fullarticle/2749213
11. Singh N, Alexander NA, Lachance K, Lewis CW, McEvoy A, Akaike G, Byrd D, Behnia S, Bhatia S, Paulson KG, Nghiem P. Clinical benefit of baseline imaging in Merkel cell carcinoma: Analysis of 584 patients. J Am Acad Dermatol. 2021 Feb;84(2):330-339. doi: 10.1016/j.jaad.2020.07.065. Epub 2020 Jul 21. PMID: 32707254; PMCID: PMC7854967.
12. George A, Girault S, Testard A, Delva R, Soulié P, Couturier OF, Morel O. The impact of (18)F-FDG-PET/CT on Merkel cell carcinoma management: a retrospective study of 66 scans from a single institution. Nucl Med Commun. 2014 Mar;35(3):282-90. doi: 10.1097/MNM.0000000000000039. PMID: 24240193.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.